Using Real World Data From the Patient Experience to Improve Drug Development

Why It Matters

Integrating RWD and SDOH into trial design enhances enrollment, accelerates market access, and drives revenue growth for oncology therapeutics.

Key Takeaways

• RCTs often overlook patient quality‑of‑life factors
• RWD reveals transport and testing access barriers
• Demographic mapping optimizes trial site placement
• Inclusive trials boost drug adoption and revenue
• SDOH integration drives patient‑centric innovation

Pulse Analysis

Real‑world data and social determinants of health are reshaping how pharmaceutical companies design and execute clinical trials. Traditional randomized controlled trials, while scientifically rigorous, frequently exclude the everyday challenges patients face—ranging from travel distance to socioeconomic constraints. By tapping into electronic health records, claims databases, and patient‑reported outcomes, sponsors gain a granular view of the patient journey, allowing them to identify gaps that standard protocols miss. This richer evidence base not only informs trial eligibility but also supports regulatory submissions that reflect broader, more representative populations.

In the context of non‑small cell lung cancer, the stakes are especially high. NSCLC patients often require complex biomarker testing and timely access to specialized care, yet many trials are situated in academic hubs far from community settings. Leveraging RWD, companies can map patient density, transportation networks, and testing availability to strategically place trial sites where they are most needed. The result is a smoother recruitment pipeline, reduced dropout rates, and data that better predicts real‑world effectiveness. The MedCity News‑PurpleLab eBook illustrates these tactics, showcasing case studies where site optimization and SDOH insights led to higher enrollment diversity and faster study completion.

Beyond enrollment, the integration of RWD and SDOH drives commercial advantage. Drugs validated in heterogeneous populations tend to achieve stronger market uptake, as payers and clinicians see evidence of effectiveness across varied patient groups. Moreover, regulators are increasingly valuing real‑world evidence in approval decisions, encouraging sponsors to embed these data streams early. As the industry embraces patient‑centric innovation, firms that master RWD analytics will likely see accelerated revenue cycles and a competitive edge in oncology and beyond.